BONTAC and NADclinic Officially Reached Strategic Cooperation for a Healthier Tomorrow!
On May 6th 2024, BONTAC and NADclinic Group signed a partnership cooperation agreement, formalizing their ambition to become deep strategic partners. Dr. Cheung (chief scientist and BONTAC founder), Mr. Shu (BONTAC CEO), Mr. Iain (NADclinic founder and CEO), and BONTAC representatives attended the signing ceremony.
Nicotinamide Adenine Dinucleotide (NAD) is a coenzyme central to metabolism that is found in all living cells. NAD+ is an essential coenzyme that converts glucose into cellular energy in the human body, supporting a healthier ageing process, driving metabolic function, supporting DNA repair, reducing inflammation, and decreasing our susceptibility to disease and chronic illness. NAD+ is necessary for over 500 critical enzymatic reactions in the body.
Along with the rapid expansion of the global NAD+ market, the NAD+ market is expected to grow exponentially in the coming years. In the era of globalization and rapid development of science and technology, bio-health industry has emerged as a key power to push economic growth and improve the life quality of human beings. By leverage of innovative medical technology, personalized therapeutic regimen and advanced bio-pharmaceuticals, the cure rate and preventive ability to disease has been greatly improved, pushing the overall improvement of global health.
With this signing, BONTAC and NADclinic will join forces to develop innovative therapies based on the cooperation concept between both parties, and promote the global research progress in the field of NAD+ by optimizing the bioavailability and medical technology. Both parties will struggle to propel the bio-health sector forward, creating a healthier and better life for human beings.
"At NADclinic, we are committed to continuing pioneering advancements in NAD+ therapeutics and nutraceuticals to empower individuals to live longer, healthier, more vibrant lives. NADclinic continues to be the benchmark brand in the NAD sector globally and working closely with BONTAC will only amplify this. "Partnering with BONTAC aligns perfectly with our own mission, allowing us to combine and consolidate our expertise and resources to deliver unparalleled solutions to our clients worldwide." said Iain De Havilland, the Founder and CEO of NADclinic.
"We are glad to officially become a deep strategic partner with NADclinic. Both parties are committed to achieving excellence and innovation in the field of NAD+ therapeutics. Through this partnership, we aim to leverage our collective expertise to provide individuals around the world with access to the highest quality NAD+ products, supporting their journey towards improved health and vitality." said Dr. Cheung, the Chief Scientist and Founder of BONTAC.
About NADclinic Group
NADclinic Group are a purveyor of NAD+ therapeutics, NAD+ supplements, and diagnostics. The NADclinic brand is trademarked internationally including the US and internationally recognized as a leader in NAD product innovation. Currently, NADclinic cooperates with 30+ leading clinical brands across the globe, with their trademark protocol menu being uniformly adopted by all preferred partners. The NADclinic brand is now active in 40 countries across 5 continents. NADclinic continue to innovate and develop the brand internationally, expanding their presence within the wellness, medical and top tier hospitality sectors. NADclinic Groups ambition to become the dominant specialist NAD brand internationally, with a particular focus within the B2B and Corporate Wellness space.
BONTAC profile
BONTAC is a national high-tech enterprise specializing in research, development, production, and sales of raw materials for coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates, with 12+ years of industry experience, self-owned factories, 170+ invention patents as well as strong R&D team. As a pioneer of NAD+ precursor (NMN) industry, BONTAC has leading whole-enzyme catalysis technology and has established the only provincial-level coenzyme engineering technology research centre in Guangdong Province, providing a variety of NAD raw material products including NAD ER Grade (to remove endotoxins), NAD I Grade (IVD/dietary supplements/cosmetic raw material powder), NAD II Grade (API/intermediates), and NAD IV Grade (if higher solubility is required). BONTAC products are widely used in nutritional health, biomedicine, medical aesthetics, daily chemical products, green agriculture, and other fields.
Nicotinamide Adenine Dinucleotide (NAD) is a coenzyme central to metabolism that is found in all living cells. NAD+ is an essential coenzyme that converts glucose into cellular energy in the human body, supporting a healthier ageing process, driving metabolic function, supporting DNA repair, reducing inflammation, and decreasing our susceptibility to disease and chronic illness. NAD+ is necessary for over 500 critical enzymatic reactions in the body.
Along with the rapid expansion of the global NAD+ market, the NAD+ market is expected to grow exponentially in the coming years. In the era of globalization and rapid development of science and technology, bio-health industry has emerged as a key power to push economic growth and improve the life quality of human beings. By leverage of innovative medical technology, personalized therapeutic regimen and advanced bio-pharmaceuticals, the cure rate and preventive ability to disease has been greatly improved, pushing the overall improvement of global health.
With this signing, BONTAC and NADclinic will join forces to develop innovative therapies based on the cooperation concept between both parties, and promote the global research progress in the field of NAD+ by optimizing the bioavailability and medical technology. Both parties will struggle to propel the bio-health sector forward, creating a healthier and better life for human beings.
"At NADclinic, we are committed to continuing pioneering advancements in NAD+ therapeutics and nutraceuticals to empower individuals to live longer, healthier, more vibrant lives. NADclinic continues to be the benchmark brand in the NAD sector globally and working closely with BONTAC will only amplify this. "Partnering with BONTAC aligns perfectly with our own mission, allowing us to combine and consolidate our expertise and resources to deliver unparalleled solutions to our clients worldwide." said Iain De Havilland, the Founder and CEO of NADclinic.
"We are glad to officially become a deep strategic partner with NADclinic. Both parties are committed to achieving excellence and innovation in the field of NAD+ therapeutics. Through this partnership, we aim to leverage our collective expertise to provide individuals around the world with access to the highest quality NAD+ products, supporting their journey towards improved health and vitality." said Dr. Cheung, the Chief Scientist and Founder of BONTAC.
About NADclinic Group
NADclinic Group are a purveyor of NAD+ therapeutics, NAD+ supplements, and diagnostics. The NADclinic brand is trademarked internationally including the US and internationally recognized as a leader in NAD product innovation. Currently, NADclinic cooperates with 30+ leading clinical brands across the globe, with their trademark protocol menu being uniformly adopted by all preferred partners. The NADclinic brand is now active in 40 countries across 5 continents. NADclinic continue to innovate and develop the brand internationally, expanding their presence within the wellness, medical and top tier hospitality sectors. NADclinic Groups ambition to become the dominant specialist NAD brand internationally, with a particular focus within the B2B and Corporate Wellness space.
BONTAC profile
BONTAC is a national high-tech enterprise specializing in research, development, production, and sales of raw materials for coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates, with 12+ years of industry experience, self-owned factories, 170+ invention patents as well as strong R&D team. As a pioneer of NAD+ precursor (NMN) industry, BONTAC has leading whole-enzyme catalysis technology and has established the only provincial-level coenzyme engineering technology research centre in Guangdong Province, providing a variety of NAD raw material products including NAD ER Grade (to remove endotoxins), NAD I Grade (IVD/dietary supplements/cosmetic raw material powder), NAD II Grade (API/intermediates), and NAD IV Grade (if higher solubility is required). BONTAC products are widely used in nutritional health, biomedicine, medical aesthetics, daily chemical products, green agriculture, and other fields.
.jpg?imageView2/1/w/360/h/200)
